Knisely Anne, Gamble Charlotte R, St Clair Caryn M, Hou June Y, Khoury-Collado Fady, Gockley Allison A, Wright Jason D, Melamed Alexander
Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York (all authors).
Department of Obstetrics and Gynecology, Columbia University Vagelos College of Physicians and Surgeons, NewYork-Presbyterian/Columbia University Irving Medical Center, New York, New York (all authors)..
J Minim Invasive Gynecol. 2021 Mar;28(3):537-543. doi: 10.1016/j.jmig.2020.11.007. Epub 2020 Nov 14.
To synthesize evidence from studies investigating survival outcomes for patients with ovarian cancer undergoing minimally invasive surgery (traditional or robotic laparoscopy) compared with those for patients with ovarian cancer undergoing laparotomy.
We searched Ovid MEDLINE and Embase (from inception to December 2019).
Observational cohort studies and randomized controlled trials that compared risk of recurrence or death between women undergoing minimally invasive and open procedures for staging (10), interval cytoreduction (4), secondary cytoreduction (2), and evaluation of resectability (1) were included.
TABULATION, INTEGRATION, AND RESULTS: Data on the number of participants, number of deaths and recurrences, and results of analyses of overall or progression-free survival were abstracted for all studies. A random-effects meta-analysis was used to pool the results of studies comparing minimally invasive staging and open staging. The surgical approach (minimally invasive versus open) was not significantly associated with hazard of death or recurrence (pooled hazard ratio 0.92; 95% confidence interval, 0.61-1.38) or all-cause mortality (pooled hazard ratio 0.96; 95% confidence interval, 0.49-1.89). One randomized trial demonstrated that diagnostic laparoscopy could triage patients to neoadjuvant chemotherapy and avoid suboptimal primary surgery, without affecting recurrence-free or overall survival. Most studies included in this review were observational and at high risk for bias, and few studies accounted for potential confounding.
Although existing studies do not demonstrate deleterious survival effects associated with minimally invasive surgery for ovarian cancer, these data must be viewed with caution given the significant methodologic shortcomings in the existing literature.
综合各项研究证据,比较接受微创手术(传统或机器人腹腔镜手术)的卵巢癌患者与接受剖腹手术的卵巢癌患者的生存结局。
我们检索了Ovid MEDLINE和Embase(从创刊至2019年12月)。
纳入观察性队列研究和随机对照试验,这些研究比较了接受微创和开放手术进行分期(10项)、中间细胞减灭术(4项)、二次细胞减灭术(2项)以及可切除性评估(1项)的女性之间的复发或死亡风险。
制表、整合与结果:提取所有研究中关于参与者数量、死亡和复发数量以及总生存或无进展生存分析结果的数据。采用随机效应荟萃分析汇总比较微创分期和开放分期的研究结果。手术方式(微创与开放)与死亡或复发风险(合并风险比0.92;95%置信区间,0.61 - 1.38)或全因死亡率(合并风险比0.96;95%置信区间,0.49 - 1.89)无显著相关性。一项随机试验表明,诊断性腹腔镜检查可将患者分流至新辅助化疗,避免进行不理想的初次手术,且不影响无复发生存或总生存。本综述纳入的大多数研究为观察性研究,存在较高的偏倚风险,且很少有研究考虑潜在的混杂因素。
尽管现有研究未证明卵巢癌微创手术对生存有有害影响,但鉴于现有文献存在显著的方法学缺陷,这些数据必须谨慎看待。